Kura Biotech
Santiago, Chile· Est.
Enzymatic‑based diagnostics platform delivering rapid, high‑efficiency testing solutions for toxicology, genomics, and food safety.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Enzymatic‑based diagnostics platform delivering rapid, high‑efficiency testing solutions for toxicology, genomics, and food safety.
ToxicologyGenomicsFood Safety
Technology Platform
Proprietary enzymatic reagents—including a high‑performance beta‑glucuronidase, high‑fidelity polymerases, and isothermal PCR enzymes—enable rapid, room‑temperature sample preparation and nucleic‑acid amplification across diagnostics and research.
Opportunities
Expansion into global diagnostic markets and leveraging enzyme stability for point‑of‑care applications present significant growth avenues.
Risk Factors
Scaling manufacturing while maintaining ISO certifications and navigating diverse regulatory environments could constrain rapid expansion.
Competitive Landscape
Kura competes with large diagnostics firms such as Thermo Fisher, QIAGEN, and Roche, but differentiates through its room‑temperature enzyme performance and rapid‑deployment capabilities.